FlashNews:

Wyndham Unwraps Year-End Holiday Gift Campaign

Your Post Went Viral. Did It Generate Any Business?

Enterprise blockchain is going to come back from the dead

How to make the perfect Vietnamese caramel pork, or thit kho – recipe | Felicity Cloake’s How to make the perfect …

The 14 best men’s boots for winter, from chelseas and lace-ups to wellies

Republicans blame everyone but Trump for midterm drubbing

The 4 Best Planners of 2027: Roterunner, Hobonichi, Cloth & Paper

AI DJs Completely Kill My Groove

Anthropic’s IPO is the next big test for AI

Here’s what happened in crypto today

OKSPOT Unveils Privacy-Focused Crypto Exchange for Global Traders With No-KYC Registration and Monero Support

FISP Overhaul and “Get Sheds Down”: What Data and System Validation Does the “Lightweight Window” for NYC Facade Retrofits Require?

Le Plaza set to shake up Geneva’s cultural scene with new hotel concept and reimagined cinema

Elysée New York Announces Reopening Following a Complete Transformation

Alleged Russell Brand rape victim wants age of consent law changed

‘It’s like you’re in one of his paintings’ Kyffin Williams’ art brought to life

AGM Unveils Solar-Storage-Charging Integrated Solution at RE+26

California Construction Estimating Services Helps Builders Make Smarter Decisions with Accurate Project Cost Estimates

Texas Cost Estimating Delivers Reliable Pricing Solutions for Residential, Commercial and Industrial Projects

OCM Globe Brings AIKO 3D Fruit Ice Cream to Brooklyn Nets AAPI Night at Barclays Center

GlobeInsights GlobeInsights
  • Home
  • Travel
  • Lifestyle
  • Entertainment
  • Fashion
  • Tech
  • Business
  • Crypto
  • Press Release
Business
120
by Noah
August 31, 2026August 31, 2026

Bristol Myers Squibb (BMY) shares have gone essentially nowhere for the past several years, and the reason comes down to two words that strike fear into pharmaceutical investors: “patent cliff.” 

Just two drugs  Eliquis and Opdivo  generated more than $24.4 billion in sales last year, roughly half of the company’s total revenue. U.S. market exclusivity on both expires in 2028, after which lower-cost generic and biosimilar competition is expected to erode that revenue base. 

Brokers from Eidellux walked through the company’s pipeline, balance sheet, and valuation to see whether the market’s skittishness has created an opportunity rather than a warning sign.

1. A revamped drug portfolio is ready to fill the gap

Pharmaceutical companies typically have years to prepare for patent expirations, and Bristol Myers Squibb has been proactively positioning itself for that challenge through both internal research and strategic acquisitions. The company currently has 50 drug candidates in development and aims to launch 10 new medicines before the end of the decade.

Among these programs, Cobenfy stands out as the most important pipeline asset. Already approved for schizophrenia, the drug could see substantial additional growth if it gains approval for Alzheimer’s disease-related psychosis. A crucial Phase 3 Adept-2 trial readout is expected later this year, making it a key catalyst for investors.

At the same time, Bristol Myers Squibb is collaborating with Johnson & Johnson on Milvexian, an experimental anticoagulant designed to treat atrial fibrillation and potentially offset future revenue declines from Eliquis. That program is also currently in Phase 3 clinical trials.

Beyond its pipeline, several recently launched products continue to deliver strong growth. In the first quarter, Camzyos sales increased 97% year over year to $314 million, Breyanzi grew 56% to $411 million, and Reblozyl rose 16% to $555 million. Overall, the company’s growth portfolio expanded 12% during the quarter, more than compensating for a 6% decline in legacy-product sales and helping drive 3% total company revenue growth.

While risks remain, particularly if Cobenfy’s Alzheimer’s-related trial results disappoint, the company appears to have multiple growth drivers already in place to help address the revenue challenges expected after 2028.

2. The 4.6% dividend looks well covered

Investors considering Bristol Myers Squibb do not need to wait for its pipeline to deliver results before seeing returns. The company currently offers a dividend yield of approximately 4.6%, and the payout appears well supported by earnings, representing only about 40% of projected 2026 earnings.

That relatively low payout ratio provides a significant margin of safety. Even in a severe scenario where sales from both Eliquis and Opdivo were eliminated, potentially reducing earnings by roughly half, the company could still have sufficient profits to support its dividend.

For income-oriented investors, the combination of a relatively high dividend yield and a conservative payout ratio is uncommon among large-cap pharmaceutical companies, making Bristol Myers Squibb an appealing option for those seeking both income and potential long-term value.

3. The valuation already prices in the bad news

Risk is part of this story, but valuation matters just as much as the risk itself. At a price-to-earnings ratio of 25, this stock would be far less attractive, since a setback in the pipeline would carry outsized downside relative to limited upside. 

Instead, Bristol Myers Squibb trades at only 8.5 times its 2026 earnings estimate, a multiple that signals the market already expects very little growth from the company.

Valuation, in that sense, functions as a read on expectations: low multiples imply low expectations, which means even modest execution can move the stock. A scenario of mid-single-digit earnings growth through the patent cliff period looks sufficient to justify the current price. At the same time, the 4.6% dividend provides a meaningful floor under total returns even if the multiple never re-rates.

 If Cobenfy’s Alzheimer’s program succeeds, that same depressed valuation could become the launchpad for substantial upside once sentiment catches up to the fundamentals.

Outlook

Bristol Myers Squibb is not without risk. The company’s 2028 patent cliff poses a significant, measurable challenge, and its long-term growth outlook depends heavily on the successful execution of its drug-development pipeline, which is far from guaranteed.

However, several factors support the investment case. Bristol Myers Squibb benefits from a diversified portfolio of newer, rapidly growing medicines, a dividend that is covered roughly twice by earnings, and a valuation that already appears to reflect a relatively cautious or pessimistic outlook.

Taken together, the stock looks more like an asymmetric opportunity than a traditional value trap. While investors must be willing to accept pipeline-related risks and potential volatility surrounding upcoming clinical milestones, the current share price may offer an attractive entry point for those prepared to hold through key catalysts over the next two to three years, given the range of potential outcomes still ahead.

Prev Post

Microsoft Stock Just Got Cheaper  Could It Actually Double From Here?

Next Post

WhatsLove AI: Top AI Companion Platforms With Real-Time Video Generation in 2026

The Latest News

  • Wyndham Unwraps Year-End Holiday Gift Campaign November 15, 2026
  • Your Post Went Viral. Did It Generate Any Business? November 15, 2026
  • Enterprise blockchain is going to come back from the dead November 15, 2026
  • How to make the perfect Vietnamese caramel pork, or thit kho – recipe | Felicity Cloake’s How to make the perfect … November 15, 2026
  • The 14 best men’s boots for winter, from chelseas and lace-ups to wellies November 15, 2026
  • Republicans blame everyone but Trump for midterm drubbing November 15, 2026
  • Latest
  • Popular
  • November 15, 2026Wyndham Unwraps Year-End Holiday Gift Campaign
  • November 15, 2026Your Post Went Viral. Did It Generate Any Business?
  • Enterprise blockchain is going to come back from the dead
    November 15, 2026Enterprise blockchain is going to come back from the dead
  • March 4, 2026A Blackstone executive made a revealing comment about the state of private credit
  • March 5, 2026Nvidia stops production of chips intended for Chinese market
  • March 3, 2026Bitcoin supply approaching 20 million: The final million will take another 114 years to mine

Most Popular

No shared posts

Globeinsights

GlobeInsights – Global Perspectives. Smarter Decisions.

Featured

  • November 15, 2026Wyndham Unwraps Year-End Holiday Gift Campaign
  • November 15, 2026Your Post Went Viral. Did It Generate Any Business?
  • Enterprise blockchain is going to come back from the dead
    November 15, 2026Enterprise blockchain is going to come back from the dead

Popular

  • March 4, 2026A Blackstone executive made a revealing comment about the state of private credit
  • March 5, 2026Nvidia stops production of chips intended for Chinese market
  • March 3, 2026Bitcoin supply approaching 20 million: The final million will take another 114 years to mine

Categories

  • Business
  • Culture
  • Fashion
  • Food
  • Tech
  • Sports
  • Travel
  • Nature
All Rights Reserved by Insight News Wire